Patents Assigned to KRIPTIC PHARMACEUTICALS LIMITED
  • Patent number: 12728158
    Abstract: The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids—native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: September 8, 2026
    Assignee: KRIPTIC PHARMACEUTICALS LIMITED
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet
  • Publication number: 20240325511
    Abstract: The invention pertains to the use of a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2)—for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing TERT.
    Type: Application
    Filed: June 14, 2024
    Publication date: October 3, 2024
    Applicant: KRIPTIC PHARMACEUTICALS LIMITED
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet, Catherine Gallou, Aude Rougeot
  • Patent number: 12048737
    Abstract: The invention pertains to the use of a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2)—for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing TERT.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: July 30, 2024
    Assignee: KRIPTIC PHARMACEUTICALS LIMITED
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet, Catherine Gallou, Aude Rougeot